Activity in certain parts of the brain appears to offer solid biomarker guideposts to whether drugs or psychotherapy works best to treat depression, researchers have found. And a pretreatment brain scan helps make the determination.
In a mixed decision, the Supreme Court has ruled that companies can not obtain a patent on human genes. But companies like Myriad Genetics will be able to nail down patent protection on complementary gene work, or cDNA, which requires human tinkering.
As the top cancer researchers gather in Chicago, the world's largest CRO is weighing in on how best to steer the future of oncology drug development, arguing that picking the right patients and biomarkers in early stages can mean the difference between a blockbuster and a late-phase failure.
In an important win for GlaxoSmithKline's R&D division, the FDA today announced that it has approved a pair of genetically targeted melanoma drugs, dabrafenib and trametinib, from the company, along with a diagnostic test that can be used to identify the patients most likely to respond to the treatments.
Researchers in California say they believe circulating tumor cells, captured and analyzed by new technology, could function as a 'liquid biopsy." If further studies confirm the effectiveness of the NanoVelcro Chip, prostate cancer could be more easily tracked over time to provide personalized treatments.
Swedish researchers believe that screening for the biomarker, perhaps with a simple urine test, could allow for more targeted treatment at an earlier enough stage to give patients a fighting chance, or at least indentify realistic options.
The preclinical CRO Cenix BioScience has struck a deal to work with Germany's Debiopharm, putting its experts to work finding predictive biomarkers that can be used to advance the biotech's cancer drug candidates.
Scientists at Georgia Regents University may have discovered the key to reversing schizophrenia, a complex disorder that affects about 1% of the U.S. population.
An enzyme inhibitor that helps repair DNA damage may provide a new way to boost the effectiveness of radiation therapy for a lethal type of brain cancer.
Bristol-Myers Squibb will collaborate with Adaptive Biotechnologies to develop immunological biomarkers for cancer, representing another step forward in the development of personalized medicine.